NR AUCW
AU Mayer-Sonnenfeld,T.; Zeigler,M.; Halimi,M.; Dayan,Y.; Herzog,C.; Lasmezas,C.I.; Gabizon,R.
TI The metabolism of glycosaminoglycans is impaired in prion diseases
QU Neurobiology of Disease 2005 Dec; 20(3): 738-43
PT journal article
AB It is well established that the conversion of PrPc to PrPsc is the key event in prion disease biology. In addition, several lines of evidence suggest that glycosaminoglycans (GAGs) and in particular heparan sulfate (HS) may play a role in the PrPc to PrPsc conversion process. It has been proposed that PrPsc accumulation in prion diseases may induce aberrant activation of lysosomal activity, which has been shown to result in neurodegeneration in a number of diseases, especially lysosomal storage disorders. Among such diseases, only the ones resulting from defects in GAGs degradation are accompanied by secretion of large amounts of GAG metabolites in urine. In this work, we show that GAGs are secreted in the urine of prion-infected animals and humans, and surprisingly, also in the urine of mice ablated for the PrP gene. We hypothesize that both the presence of PrPsc or the absence of PrPc may alter the metabolism of GAGs.
MH Animals; Brain/*metabolism/pathology/physiopathology; Creutzfeldt-Jakob Syndrome/genetics/physiopathology/urine; Cricetinae; Disease Models, Animal; Enzyme Activation/genetics; Glycosaminoglycans/*urine; Hexosaminidases/metabolism; Humans; Lysosomes/metabolism; Male; Mice; Mice, Knockout; Neurons/metabolism; PrPc Proteins/genetics/*metabolism; PrPsc Proteins/*metabolism; Prion Diseases/genetics/physiopathology/*urine; Scrapie/genetics/physiopathology/urine; Sheep; Up-Regulation/genetics
AD Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, Jerusalem, 91120 Israel.
SP englisch
PO USA